In another advanced orthotopic ovarian cancer model, intraperitoneal administration of HA-LNPs loaded with a combination of eukaryotic translation-initiation factor 3c (eIF3c) and PLK1 siRNA resulted in robust gene silencing in tumor tissues, with a remarkably enhanced overall survival of 60% achieved compared with unmodified and single siRNA-loaded LNPs (Singh et al.2021). This evidence concerns the gene PLK1 and ovarian cancer.